GlassScriptPhysician profile
Jaime Estrada
NPI 1396792065
$671.62
in general payments reported to CMS, 2019-2025
8 companies · $92.92 in 2025
The $92.92 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $79.03 · 2022: $42.89 · 2024: $19.02 · 2025: $92.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $145.90 | 2019-2020 | |
| Biogen, INC. | $122.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $120.44 | 2019 | |
| Glaxosmithkline, LLC. | $82.40 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $80.32 | 2019 | |
| Genentech USA, INC. | $48.05 | 2019 | |
| Sumitomo Pharma America, INC. | $45.91 | 2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $26.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.